Journal of Bone and Mineral Metabolism

, Volume 27, Issue 1, pp 114–119 | Cite as

The generation of osteoclasts from RAW 264.7 precursors in defined, serum-free conditions

  • Cristina Vincent
  • Masakazu Kogawa
  • David M. Findlay
  • Gerald J. Atkins
Short Communication

Abstract

Osteoclasts are the unique cell type capable of resorbing bone. The discovery of the TNF-ligand family member, RANKL, has allowed more reliable study of these important cells. The mouse monocytic cell line, RAW 264.7, has been shown to readily differentiate into osteoclasts upon exposure to recombinant RANKL. Unlike primary osteoclast precursors, there is no requirement for the addition of macrophage colony stimulating factor (M-CSF). However, to date, their differentiation has always been studied in the context of added foetal calf serum (FCS). FCS is a complex and largely undefined mixture of growth factors and matrix proteins, and varies between batches. For this reason, osteoclastogenesis would ideally be studied in the context of a defined, serum-free medium. RAW 264.7 cells were cultured in serum-replete α-MEM or serum-deprived medium (SDM) shown previously to support the growth of human osteoclasts in a co-culture with normal osteoblasts. In SDM, in the presence of recombinant RANKL, RAW 264.7 cells readily differentiated into tartrate resistant acid phosphatase (TRAP) positive multinucleated osteoclast-like cells, a process that was enhanced with the addition of 1α,25-dihydroxyvitamin D3 (1,25D). While the osteoclasts grown in SDM were smaller in size compared with those derived in serum-replete media, their resorptive capacity was significantly increased as indicated by a twofold increase in average resorption pit size. In conclusion, we describe a defined model for studying osteoclast differentiation and activity in the absence of serum, which will be ideal for studying the role of agonistic and antagonistic molecules in this process.

Keywords

Osteoclast Osteoclastogenesis RAW 264.7 Differentiation RANKL 

Notes

Acknowledgments

GJA was supported by a National Health and Medical Research Council of Australia (NHMRC) R. Douglas Wright Fellowship. MK was supported by an Australian federal government Endeavour (Post-Doctoral) Fellowship. This study was supported by an NHMRC Project grant.

References

  1. 1.
    Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165–176PubMedCrossRefGoogle Scholar
  2. 2.
    Matsuzaki K, Katayama K, Takahashi Y, Nakamura I, Udagawa N, Tsurukai T, Nishinakamura R, Toyama Y, Yabe Y, Hori M, Takahashi N, Suda T (1999) Human osteoclast-like cells are formed from peripheral blood mononuclear cells in a coculture with SaOS-2 cells transfected with the parathyroid hormone (PTH)/PTH-related protein receptor gene. Endocrinology 140:925–932PubMedCrossRefGoogle Scholar
  3. 3.
    Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Boyle WJ et al (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89:309–319PubMedCrossRefGoogle Scholar
  4. 4.
    Teitelbaum SL (2007) Osteoclasts: what do they do and how do they do it? Am J Pathol 170:427–435PubMedCrossRefGoogle Scholar
  5. 5.
    Tsuda E, Goto M, Mochizuki S, Yano K, Kobayashi F, Morinaga T, Higashio K (1997) Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem Biophys Res Commun 234:137–142PubMedCrossRefGoogle Scholar
  6. 6.
    Gronthos S, Simmons PJ (1995) The growth factor requirements of STRO-1-positive human bone marrow stromal precursors under serum-deprived conditions in vitro. Blood 85:929–940PubMedGoogle Scholar
  7. 7.
    Atkins GJ, Kostakis P, Welldon KJ, Vincent C, Findlay DM, Zannettino AC (2005) Human trabecular bone-derived osteoblasts support human osteoclast formation in vitro in a defined, serum-free medium. J Cell Physiol 203:573–582PubMedCrossRefGoogle Scholar
  8. 8.
    Atkins GJ, Kostakis P, Vincent C, Farrugia AN, Houchins JP, Findlay DM, Evdokiou A, Zannettino AC (2006) RANK expression as a cell surface marker of human osteoclast precursors in peripheral blood, bone marrow, and giant cell tumors of bone. J Bone Miner Res 21:1339–1349PubMedCrossRefGoogle Scholar
  9. 9.
    Atkins GJ, Bouralexis S, Haynes DR, Graves SE, Geary SM, Evdokiou A, Zannettino AC, Hay S, Findlay DM (2001) Osteoprotegerin inhibits osteoclast formation and bone resorbing activity in giant cell tumors of bone. Bone 28:370–377PubMedCrossRefGoogle Scholar
  10. 10.
    Hsu H, Lacey DL, Dunstan CR, Solovyev I, Colombero A, Timms E, Tan HL, Elliott G, Kelley MJ, Sarosi I, Wang L, Xia XZ, Elliott R, Chiu L, Black T, Scully S, Capparelli C, Morony S, Shimamoto G, Bass MB, Boyle WJ (1999) Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 96:3540–3545PubMedCrossRefGoogle Scholar
  11. 11.
    Hayman EG, Ruoslahti E (1979) Distribution of fetal bovine serum fibronectin and endogenous rat cell fibronectin in extracellular matrix. J Cell Biol 83:255–259PubMedCrossRefGoogle Scholar
  12. 12.
    Robey GP, Boskey AL (2003) Extracellular matrix and biomineralization of bone. In: Primer on the metabolic bone diseases and disorders of mineral metabolism, 5th edn. American Society for Bone and Mineral Research, Washington DC, pp 38–46Google Scholar
  13. 13.
    Helfrich MH, Nesbitt SA, Dorey EL, Horton MA (1992) Rat osteoclasts adhere to a wide range of RGD (Arg–Gly–Asp) peptide-containing proteins, including the bone sialoproteins and fibronectin, via a beta 3 integrin. J Bone Miner Res 7:335–343PubMedGoogle Scholar
  14. 14.
    Nakamura I, Takahashi N, Sasaki T, Jimi E, Kurokawa T, Suda T (1996) Chemical and physical properties of the extracellular matrix are required for the actin ring formation in osteoclasts. J Bone Miner Res 11:1873–1879PubMedCrossRefGoogle Scholar
  15. 15.
    Malone JD, Teitelbaum SL, Griffin GL, Senior RM, Kahn AJ (1982) Recruitment of osteoclast precursors by purified bone matrix constituents. J Cell Biol 92:227–230PubMedCrossRefGoogle Scholar
  16. 16.
    Wright LM, Maloney W, Yu X, Kindle L, Collin-Osdoby P, Osdoby P (2005) Stromal cell-derived factor-1 binding to its chemokine receptor CXCR4 on precursor cells promotes the chemotactic recruitment, development and survival of human osteoclasts. Bone 36:840–853PubMedCrossRefGoogle Scholar
  17. 17.
    Suzuki K, Zhu B, Rittling SR, Denhardt DT, Goldberg HA, McCulloch CA, Sodek J (2002) Colocalization of intracellular osteopontin with CD44 is associated with migration, cell fusion, and resorption in osteoclasts. J Bone Miner Res 17:1486–1497PubMedCrossRefGoogle Scholar
  18. 18.
    Boissy P, Machuca I, Pfaff M, Ficheux D, Jurdic P (1998) Aggregation of mononucleated precursors triggers cell surface expression of alphavbeta3 integrin, essential to formation of osteoclast-like multinucleated cells. J Cell Sci 111(Pt 17):2563–2574PubMedGoogle Scholar
  19. 19.
    Nakamura I, Tanaka H, Rodan GA, Duong LT (1998) Echistatin inhibits the migration of murine prefusion osteoclasts and the formation of multinucleated osteoclast-like cells. Endocrinology 139:5182–5193PubMedCrossRefGoogle Scholar
  20. 20.
    Fuller K, Wong B, Fox S, Choi Y, Chambers TJ (1998) TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J Exp Med 188:997–1001PubMedCrossRefGoogle Scholar
  21. 21.
    Arai F, Miyamoto T, Ohneda O, Inada T, Sudo T, Brasel K, Miyata T, Anderson DM, Suda T (1999) Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) receptors. J Exp Med 190:1741–1754PubMedCrossRefGoogle Scholar
  22. 22.
    Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, Morony S, Oliveira-dos-Santos AJ, Van G, Itie A, Khoo W, Wakeham A, Dunstan CR, Lacey DL, Mak TW, Boyle WJ, Penninger JM (1999) OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397:315–323PubMedCrossRefGoogle Scholar
  23. 23.
    Kearns AE, Khosla S, Kostenuik P (2007) RANKL and OPG Regulation of Bone Remodeling in Health and Disease. Endocr Rev 29(2):155–192PubMedCrossRefGoogle Scholar
  24. 24.
    Kim HJ, Zhao H, Kitaura H, Bhattacharyya S, Brewer JA, Muglia LJ, Patrick Ross F, Teitelbaum SL (2007) Glucocorticoids and the osteoclast. Ann NY Acad Sci 1116:335–339PubMedCrossRefGoogle Scholar
  25. 25.
    Husheem M, Nyman JK, Vaaraniemi J, Vaananen HK, Hentunen TA (2005) Characterization of circulating human osteoclast progenitors: development of in vitro resorption assay. Calcif Tissue Int 76:222–230PubMedCrossRefGoogle Scholar
  26. 26.
    Sivagurunathan S, Muir MM, Brennan TC, Seale JP, Mason RS (2005) Influence of glucocorticoids on human osteoclast generation and activity. J Bone Miner Res 20:390–398PubMedCrossRefGoogle Scholar
  27. 27.
    Takuma A, Kaneda T, Sato T, Ninomiya S, Kumegawa M, Hakeda Y (2003) Dexamethasone enhances osteoclast formation synergistically with transforming growth factor-beta by stimulating the priming of osteoclast progenitors for differentiation into osteoclasts. J Biol Chem 278:44667–44674PubMedCrossRefGoogle Scholar
  28. 28.
    Medhora MM, Teitelbaum S, Chappel J, Alvarez J, Mimura H, Ross FP, Hruska K (1993) 1 alpha, 25-dihydroxyvitamin D3 up-regulates expression of the osteoclast integrin alpha v beta 3. J Biol Chem 268:1456–1461PubMedGoogle Scholar
  29. 29.
    Andersson G, Johansson EK (1996) Adhesion of human myelomonocytic (HL-60) cells induced by 1, 25-dihydroxyvitamin D3 and phorbol myristate acetate is dependent on osteopontin synthesis and the alpha v beta 3 integrin. Connect Tissue Res 35:163–171PubMedCrossRefGoogle Scholar
  30. 30.
    Kido S, Inoue D, Hiura K, Javier W, Ito Y, Matsumoto T (2003) Expression of RANK is dependent upon differentiation into the macrophage/osteoclast lineage: induction by 1alpha, 25-dihydroxyvitamin D3 and TPA in a human myelomonocytic cell line, HL60. Bone 32:621–629PubMedCrossRefGoogle Scholar
  31. 31.
    Zhang Q, Fong CC, Zhang Y, Tzang CH, Fong WF, Yang M (2008) cDNA microarray analysis of the differentially expressed genes involved in murine pre-osteoclast RAW264.7 cells proliferation stimulated by dexamethasone. Life Sci 82:135–148PubMedCrossRefGoogle Scholar

Copyright information

© The Japanese Society for Bone and Mineral Research and Springer 2008

Authors and Affiliations

  • Cristina Vincent
    • 1
  • Masakazu Kogawa
    • 1
  • David M. Findlay
    • 1
  • Gerald J. Atkins
    • 1
  1. 1.Bone Cell Biology Group, Discipline of Orthopaedics and TraumaUniversity of Adelaide and the Hanson InstituteAdelaideAustralia

Personalised recommendations